Generation Bio Co.
generationbio.comWhat Do They Do?
Develops treatments for people with autoimmune diseases by using targeted nanoparticles to silence disease-driving genes in T cells, a type of immune cell.
10-K for FY2024, filed Mar 13, 2025
How Do They Make Money?
Moderna reimburses Generation Bio for research costs; the company may also receive upfront fees, milestone payments when specified events occur, and royalties on sales of licensed products.
10-K for FY2024, filed Mar 13, 2025
$19.9M
-
10-K for FY2024, filed Mar 13, 2025
$19.9M ↗
Who Are Their Customers?
Moderna is the collaboration partner, reimbursing research costs and holding options to license specified products; the agreement covers preclinical research programs.
10-K for FY2024, filed Mar 13, 2025In March 2023, we entered into the Collaboration Agreement, with Moderna, to collaborate on developing treatments for certain diseases by…View ↗
The research programs will be conducted pursuant to research plans and associated research budgets established by governance committees…View ↗
In addition, Moderna has exclusive options, upon payment of option exercise fees, to obtain worldwide, exclusive, sublicensable licenses…View ↗
Do Revenues Turn Into Profits?
No. It lost $131.7M in FY2024.
10-K for FY2024, filed Mar 13, 2025
−$142.4MView ↗
10-K for FY2024, filed Mar 13, 2025
−$131.7MView ↗
10-K for FY2024, filed Mar 13, 2025
−$91MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q3 FY2025, filed Nov 5, 2025
−$5.5MView ↗
- ▼ −64% (Loss)
- vs −$15.3M in Q3 FY2024
-
Feb 9, 2026
XOMA completed its acquisition of Generation Bio
The offer provided $4.2913 per share in cash plus one contingent value right.
Sources
8-K, filed Feb 9, 2026
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on January 9, 2026, Parent and Merger Sub…View ↗
-
Dec 15, 2025
Generation Bio agreed to be acquired by XOMA
The proposed offer combined cash per share with one contingent value right.
Sources
8-K, filed Dec 15, 2025
On December 15, 2025, Generation Bio Co., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger…View ↗
-
Oct 22, 2025
McDonough left the CEO role; Howze became interim CEO
McDonough continued as board chair after stepping down as CEO.
Sources
8-K, filed Oct 22, 2025
On October 21, 2025, Generation Bio Co. (the “Company”) and Geoff McDonough, M.D. agreed that Dr. McDonough would resign from the Company…View ↗
From broad genetic medicines to autoimmune treatments
The older report described a genetic-medicine platform for liver, retina, and other diseases; the latest report focuses on developing siRNA treatments that silence targets in T cells for autoimmune diseases.
10-K for FY2021, filed Feb 24, 2022 10-K for FY2024, filed Mar 13, 2025
Who Do They Compete With?
Competes with argenx, Kymera Therapeutics, Monte Rosa Therapeutics, Nurix Therapeutics, Amgen, AbbVie, Hoffmann La Roche, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Wave Life Sciences, Capstan Therapeutics, Orna Therapeutics, and Moderna
10-K for FY2024, filed Mar 13, 2025There are numerous companies that are selling or developing medicines treating autoimmune diseases, including in indications for which we…View ↗
Loading...
